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Background and purpose: Undifferentiated follicular and anaplastic thyroid tumours often respond poorly
to radiotherapy and show increased metastatic potential. We evaluated radiation-induced effects on
metastasis in thyroid carcinoma cells and tumours, mechanistically focusing on phosphatidylinositide
3-kinase (PI3K) and associated pathways.
Material and methods: Migration was analysed in follicular (FTC133) and anaplastic (8505c) cells follow-
ing radiotherapy (0–6 Gray) with concomitant pharmacological (GDC-0941) or genetic inhibition of PI3K.
Hypoxia-inducible factor-1 (HIF-1)-activity was measured using luciferase reporter assays and was inhib-
ited using a dominant-negative variant. Activation and subcellular localisation of target proteins were
assessed via Western blot and immunoﬂuorescence. In vivo studies used FTC133 xenografts with meta-
static lung dissemination assessed ex vivo.
Results: Radiation induced migration in a HIF-dependent manner in FTC133 cells but decreased migra-
tion in 8505c’s. Post-radiation HIF-activity correlated with migratory phenotype. PI3K-targeting inhibited
migration under basal and irradiated conditions through inhibition of HIF-1a, Rho-GTPase expression/
activity and localisation whilst having little effect on src/FAK. In vivo, radiation induced PI3K, HIF, Rho-
GTPases and src but only PI3K, HIF and Rho-GTPases were inhibited by GDC-0941. Co-treatment with
GDC-0941 and radiation signiﬁcantly reduced metastatic dissemination versus radiotherapy alone.
Conclusions: Radiation modiﬁes metastatic characteristics of thyroid carcinoma cells, which can be suc-
cessfully inhibited by targeting PI3K using GDC-0941 in vitro and in vivo.
 2013 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy
and Oncology 108 (2013) 548–553
Open access under CC BY-NC-ND license.Radiotherapy is a ﬁrst line treatment of thyroid carcinoma. The
majority of differentiated tumours respond well, however some
follicular (FTC) and anaplastic (ATC) thyroid cancers are radio-
resistant and metastatic. Patients that show recurrent local dis-
ease post-radiotherapy usually have lower survival rates due to
an increased probability of developing distant metastasis [1–3].
The phosphatidylinositide 3-kinase (PI3K) pathway has been
implicated in driving metastatic phenotype in thyroid [4–5] and
other cancers [6–8] and PI3K activity is increased by radiotherapy
in certain tumours [9–10]. PI3K has pleiotropic effects, forcing
metastatic transition via enhanced epithelial-mesenchymal tran-sition (EMT), migration (Vimentin), cell adhesion, spreading (N-
cadherin) [8,11] and invasion (matrix-metallo proteinases:
MMPs) [12]. Mechanistically the PI3K pathway interacts with
the Rho-GTPases (Rac1, Cdc42 and Rho) that regulate the dy-
namic reorganisation of the actin cytoskeleton [13] and the fo-
cal-adhesion associated proteins src and focal-adhesion kinase
(src and FAK) [14–16] that promote cell adhesion and movement.
We have previously shown that PI3K activates hypoxia-inducible
factor-1 (HIF-1) in thyroid tumours and that both pathways con-
tribute signiﬁcantly to metastatic behaviour in this disease [4,17].
Given the signiﬁcant link between the PI3K/HIF pathways and
metastasis in thyroid carcinoma and the clinical association be-
tween post-radiotherapy recurrent and distant metastasis, we as-
sessed the effect of radiotherapy on the metastatic behaviour of
FTC/ATC cell lines and FTC tumours with hyperactive PI3K signal-
ling. We further explored how PI3K inhibition via the clinically
relevant inhibitor GDC-0941 mechanistically impacted on these
phenotypes, with particular attention to src/FAK, the Rho-GTPases
and HIF-1 activation.
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Cell lines
ATC (8505c), FTC (FTC133,WRO) andderivative cell lines (includ-
ing gifts of FTC133 PTEN and PCI-NEO from Professor Oliver Gimm,
University of Linkoping, Sweden) are described previously [4].Scratch-wound migration assay
Protocols were adapted from those previously described [4].
Brieﬂy, scratched monolayers of quiescent cells were incubated
with media supplemented with 0.2% foetal calf serum (FCS) con-
taining either GDC-0941 (Chemdea, NJ, USA) or DMSO (Sigma–Al-
drich, Gillingham, UK) for 4 h, irradiated under ambient conditions
using a Faxitron X-ray (dose rate 0.952 Gy/min; Faxitron Bioptics,
AZ, USA) at 0, 2, 4 or 6 Gray (Gy) and incubated in condition for
a further 16 or 20 h depending on study. Images were captured
and analysed as previously described [4].
HIF-1 activity assay
An adenoviral-based luciferase reporter assay was used to mea-
sure HIF-1 activation as previously described [17]. Brieﬂy infected
cells treated with 1 lM GDC-0941 or DMSO were incubated for
18 h, irradiated (0–6 Gy) then incubated for a further 4 h. Cells
were lysed and HIF-induced luciferase activity quantiﬁed.
Immunoﬂuorescence
Cells were ﬁxed with 10% formalin for 10 min at room tempera-
ture (RT), permeabilised with 0.1% Triton X100 in phosphate buf-
fered saline (PBS) for 7 min and blocked with 1% BSA in PBS for
30 min at RT. Cells were incubated with the appropriate primary
antibody for 1 h at 37 C, washed and incubated with a secondary
Alexaﬂuor (Life Technologies Ltd., Paisley, UK) for 45 min at 37 C.
Cells were mounted and images obtained at 400magniﬁcation as
described above.
Western-blotting
Protocolswereused aspreviouslydescribed [17]. For Rho-GTPas-
es/src/FAKanalysis60–70 lgproteinwas loaded. Proteinexpression
was quantiﬁed via densitometry relative to b-actin, using ImageJ.
Primary antibodies
Listed in Supplementary methods.Xenograft studies
FTC133 cells were implanted sub-cutaneously (0.1 ml of a
5  107/ml stock in PBS) in female nude mice (CBA nu/nu, aged
8–12 weeks). Radiotherapy commenced when tumours reached
200–250 mm3 [18]. GDC-0941 was prepared in 0.5% hydroxypro-
pyl methyl cellulose (vehicle) and dosed at 0.1 ml/10 g body
weight by oral gavage (p.o.). Mice were dosed twice daily with
vehicle or 50 mg/kg GDC-0941 alone or combined with radiation
(5  2 Gy fractions over 5 consecutive days). Mice received GDC-
0941 4 h prior and immediately after radiation. For histology, tu-
mours were rapidly excised 1 h after the ﬁnal dose of vehicle/
GDC-0941 and snap frozen. For metastasis analysis, dosing contin-
ued post-radiotherapy for a further 9 days. Once tumours reached
maximum burden (approximately 900 mm3), the lung tissue was
excised and analysed for metastatic colonies as described in [4].
All procedures were carried out in accordance with the Scientiﬁc
Procedures Act 1986 and published guidelines [19] with ethically
approved protocols, using the highest standard of welfare underthe authority of the Home Ofﬁce (PPL40/3112, holder Professor
K.J. Williams).Statistical analysis
Student’s t test and one-way ANOVA with Tukey post-test were
used.
Results
Radiation-induced migratory effects are associated with HIF-1
activation and are blocked by PI3K inhibition
We determined if radiation affected the migratory phenotype of
follicular (FTC133, WRO) and anaplastic (8505c) thyroid carcinoma
cells in vitro. Migration increased in a radiation dose-dependent
manner in FTC133 and WRO cells (Fig. 1A and Supplementary
Fig. 1). Under hypoxia (1% oxygen) consistent with our previous
data [4], hypoxia alone induced migration but no further response
was observed with combined radiation treatment (Supplementary
Fig. 1). In 8505c cells, radiation decreased migratory phenotype in
both aerobic and hypoxic conditions (Fig. 1B and Supplementary
Fig. 1). These cells exhibit a maximal migratory capacity in air
and hypoxia alone has little effect [4]. HIF-1 activity was assessed
in response to radiation treatment and correlated with the radia-
tion-induced migratory phenotypes observed (Figs. 1A and B). Inhi-
bition of HIF-1 activity in FTC133s through stable expression of a
dominant-negative variant of HIF-1a (dnHIF) abrogated radia-
tion-induced migration (Fig. 1C). Inhibition of PI3K via two inde-
pendent methods; pharmacological and genetic, abrogated
radiation-mediated migration: 1 lM GDC-0941 inhibited both
migratory phenotype and the activity of HIF-1 in both FTC133
and 8505c cells (Fig. 1A and B). Re-introduction of PTEN into the
PTEN-null FTC133 cells similarly inhibited migration (Fig. 1D).Inhibition of PI3K via GDC-0941 inhibits HIF-1a and the Rho-GTPases
whilst having no effect on the src/FAK axis in vitro
The effects of radiotherapy on activation/expression of PI3K-
associated proteins involved in the mechanics of cell migration
were ascertained by Western-blot analysis. In both FTC133 and
8505c cells, radiotherapy had little effect on AKT or src activation
(pY416), src mediated activation of FAK (pY861), FAK autophos-
phorylation (pY397), the association of Rac1 with Cdc42 (Rac1/
Cdc42-pS7) or expression of Rho (Fig. 2A, Supplementary
Fig. 2A). Subcellular localisation of pAKT or pFAK (pY861) was sim-
ilarly uninﬂuenced by radiation (Fig. 2B, Supplementary Fig. 2B).
However, in both cell types, radiation caused marked changes in
the subcellular localisation of Rac1/Cdc42-pS71 and Rho (Fig. 2B
and C and Supplementary Fig. 2B and C), with cell lines exhibiting
increased accumulation of Rac1/Cdc42-pS71 into focal adhesions
in lamellipodia and alterations in Rho subcellular-localisation
(Fig. 2B and C, Supplementary Fig. 2B and C). HIF-1a expression
was also altered by radiotherapy. To explore how GDC-0941 mech-
anistically inhibited migration, effects on phosphorylation and
activation of the PI3K-associated migratory proteins were as-
sessed. In both cell lines, GDC-0941 had no effect on src/FAK but
clearly inhibited the PI3K/HIF-1/Rho-GTPase signalling axis
(Fig. 2, Supplementary Fig. 2).
In vivo, radiotherapy increases PI3K, Rho-GTPase, HIF-1 and src
activity with GDC-0941 cotreatment inhibiting only the PI3K/HIF-1/
Rho-GTPase axis
Mice bearing FTC xenografts were irradiated (2 Gy for 5 consec-
utive days) with or without additional GDC-0941 treatment
(50 mg/kg twice daily) and expression of PI3K-regulated
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Fig. 1. Radiation modulates migratory potential and HIF activity, which is blocked by PI3K inhibition. (A and B) Radiotherapy dose-dependently increases migration in
FTC133 cells and decreases migration in 8505c cells which correlates with changes in HIF-activity. GDC-0941 signiﬁcantly inhibits migration and HIF-activation. (C) dnHIF
expression inhibits radiation-induced migration in FTC133 cells. (D) Genetic inhibition of PI3K via re-introduction of PTEN into PTEN-null FTC133 cells inhibits radiation-
induced migration versus vector only (PCI-NEO) control cells. Data represent the mean ± S.D. of 3–4 independent experiments; ⁄p < 0.01, ⁄⁄p < 0.001, ⁄⁄⁄p < 0.0001 versus
relevant untreated control.
550 GDC-0941 inhibits radiation-induced metastasismetastatic proteins assessed by Western-blotting in comparison
with size-matched control vehicle treated tumours. In contrast
with in vitro treatments, radiation clearly induced both PI3K
(AKT-pS473) and src (src-pY416; FAK-pY861) in addition to
enhancing Rho-GTPase activity/expression. Little evidence of FAK
activation was observed (FAK-pY397). Radiation also induced
expression of HIF-1a and selective downstream targets associated
with metastatic phenotype in vivo. GDC-0941 treatment inhibited
PI3K, Rho-GTPase activity/expression, HIF-1a and downstream tar-
gets Vimentin, MMP-2 and MMP-9 whilst having no effect on src/
FAK or N-cadherin (Fig. 3A and B; Supplementary Figs. 3 and 4).GDC-0941 inhibits metastatic lung colonisation in irradiated FTC
xenografts
The FTC133 model spontaneously metastasises to the lung from
the primary sub-cutaneous implant site. We previously showed
that GDC-0941 inhibited lung metastasis in mice bearing FTC
xenografts [4]. To explore the effect of GDC-0941 in combination
with radiotherapy on tumour metastasis, tumours were treated
as detailed (Methods) and the lung tissue harvested once tumours
reached maximum burden (approximately 900 mm3 achieved on
average at days 7, 31 and 35 for control, irradiated and tumours
co-treated with GDC-0941 and radiotherapy, respectively).
Lung-tumour burden was quantiﬁed using an ex vivo clonogenic
assay [4]. The lungs from mice bearing irradiated tumours had sig-
niﬁcantly more metastatic colonies compared to non-irradiated
controls, which perhaps reﬂects the relative excision timeframe.When combined with radiation, GDC-0941 halved the metastatic
colonisation to the lungs observed with radiation alone (Fig. 3C).Discussion
Radiotherapy is a ﬁrst line treatment in many cancers including
thyroid but may promote metastasis. Clinically, patients with
recurrent local disease post radiotherapy usually have lower sur-
vival rates due to increased distant metastasis. Here we provide
important evidence that radiotherapy modulates the metastatic
phenotype in thyroid carcinoma, which appears dependent on
interplay between the PI3K and HIF-1 signalling pathways. PI3K
activates HIF-1 in thyroid carcinoma cells, which increases meta-
static potential [4]. Here we show that radiation-induced changes
in cell motility link to radiation-modulated HIF-1 activity that is
dependent on PI3K. Radiation dose-dependently increased HIF-1
activity in FTC133 cells and inhibition of HIF-1 via a dominant neg-
ative variant abrogated radiation-induced migratory phenotype. In
8505c cells where radiotherapy reduced HIF-1 activity, also re-
duced migratory phenotype, further supporting that HIF activity
relates directly to migratory phenotype. It is important to note that
8505c’s are primed for maximal migration under normoxia and ba-
sal HIF-1 activation in this cell line is higher compared with
FTC133s cells [17]. This may reﬂect the relative differences ob-
served between the two cell lines in HIF-mediated responses to
radiotherapy. The use of GDC-0941, a clinically relevant inhibitor
of PI3K inhibited both HIF-1 activity and migratory phenotype in
follicular and anaplastic thyroid cell lines. Mechanistically we
show that the anti-migratory effects of GDC-0941 appear elicited
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N. Burrows et al. / Radiotherapy and Oncology 108 (2013) 548–553 551via impact on the Rho-GTPase axis whilst having little effect on src
or FAK. These data are supported by work showing that inhibition
of the PI3K-regulated protein mammalian target of rapamycin
(mTOR) by rapamycin also inhibited expression of the Rho-GTPas-
es [20]. Conversely to GDC-0941, rapamycin also inhibited FAK
activation. Our data suggest that GDC-0941 blocks migration via
selective targeting of two distinct signalling axes: PI3K/Rho-
GTPase and PI3K/HIF-1.
Radiation treatment in vitro did not alter expression/activity of
PI3K, src/FAK or Rho-GTPases but did cause marked changes in thesubcellular localisation of the latter proteins. Localisation of the
Rho- GTPases differed between the FTC133 and 8505c cells, which,
in addition to differences in HIF-1, may contribute to the observed
differences in migratory phenotype. In contrast, radiation treat-
ment of FTC133 xenografts in vivo caused activation of PI3K, src
and Rho-GTPases as well as inducing HIF-1a and downstream tar-
gets. FAK autophosphorylation was not observed, suggesting that
FAK is not fully activated by radiotherapy in this model. The strik-
ing differences between pathway activation in vitro and in vivo
likely reﬂect the contribution of the extracellular matrix in the
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552 GDC-0941 inhibits radiation-induced metastasislatter case, which is well known to inﬂuence cell survival following
radiation treatment [21]. GDC-0941 inhibited radiation-induced
PI3K, HIF-1 and Rho-GTPase activity, but, as in the in vitro scenario,
had no effect on src. Although previous reports have suggested
PI3K-mediated activation of src [14]: this does not occur following
radiation treatment of follicular thyroid carcinoma xenografts.
Consistent with the inhibitory effects of GDC-0941 on migratory
phenotype in vitro, GDC-0941 reduced metastatic dissemination
of FTC133 xenografts in vivo. Radiation alone saw an increase in
lung tumour clonogens compared with control tumours. However
this cannot be interpreted simply as radiation promoting meta-
static phenotype as the radiation treatment induces a substantialdelay in tumour growth such that the lung burden can accumulate
over an increased period of time. Lung dissemination was halved
with GDC-0941 and there was no detrimental effect to the primary
tumour response with the co-treatment. Indeed in these animals,
tumour excision was delayed by 4 days compared with radiother-
apy alone. These data support the development of PI3K inhibition
in combination with radiotherapy to improve overall disease free
survival.
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